Polyrizon Ltd. announced on June 17, 2026, that it received notice of a U.S. patent publication regarding its mucoadhesive drug delivery platform. The company incorporated this announcement into its existing SEC registration statements. Polyrizon Ltd. is a biotechnology company developing drug delivery technologies.
